A deep dive into the Fc–FcR axis as a therapeutic anchor in autoimmune disease, examining immune signaling and drug ...
A recent study by Vanderbilt Health researchers has revealed a greater, detrimental role for B lymphocytes (B cells) in the ...
Novartis intends to submit ianalumab for regulatory approval globally in early 2026.
Each immune cell group has distinct metabolic requirements, activation pathways, and cytokine reliance. Standard, one-size-fits-all media cannot address these features. When studying diverse cell ...
A newly identified mechanism lends credence to the idea that MS may be treatable by targeting EBV-infected B-cells, a study found.
The FDA has granted breakthrough therapy designation to Novartis’ ianalumab for Sjögren’s disease, according to a press release from the manufacturer.In its statement, Novartis said it plans to submit ...
Ianalumab receives FDA Breakthrough Therapy status for Sjögren disease following positive findings from two phase 3 clinical trial programs.
US FDA grants Breakthrough Therapy designation to Novartis’ ianalumab for Sjögren’s disease: Basel Monday, January 19, 2026, 12:00 Hrs [IST] Novartis announced that the US Fo ...
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Novartis’ ianalumab for Sjögren’s ...
Novartis has announced that ianalumab has received Breakthrough Therapy designation from the US FDA to treat Sjögren’s disease.
Hepatocellular carcinoma (HCC), characterized by high aggressiveness and recurrence, poses a significant global health challenge. The interplay between the tumour microenvironment and exogenous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results